An observational study in Chronic Idiopathic Thrombocytopenic Purpura, sponsored by Kissei Pharmaceutical Co., Ltd.. Recruiting at 1 site in Japan. Per ClinicalTrials.gov, last updated 2025-01-03.
Sponsored by Kissei Pharmaceutical Co., Ltd. · Observational
The purpose of this survey is evaluating the safety and efficacy of long-term administration of fostamatinib for Japanese patients with chronic idiopathic thrombocytopenic purpura under actual conditions of use.
The purpose of this survey is evaluating the safety and efficacy of long-term administration of fostamatinib for Japanese patients with chronic idiopathic thrombocytopenic purpura under actual conditions of use.
503 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 158 are open to participants now.
This study's planned enrollment of 149 is above the median of 122 across 99 observational studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Browse Purpura, Thrombocytopenic, Idiopathic studies →Kissei Pharmaceutical Co., Ltd. is the lead sponsor of 63 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with chronic idiopathic thrombocytopenic purpura who are treatment with fostamatinib for the first time.
Inclusion Criteria:
Drug: fostamatinib
oral administration
Adverse events
Time frame: 18 months
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Purpura, Thrombocytopenic, Idiopathic →
Kissei Pharmaceutical Co., Ltd. →